TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation

NCT06802081 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether the medication tirzepatide can help reduce obesity in adults who also have atrial fibrillation.

Status Recruiting Currently enrolling participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 100 people Planned (estimated).

Who can join Ages 18–80 · all sexes

Timeline Started 2025-04 · est. completion 2027-06

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT06802081 ↗

Description as written by the study sponsor.

This is a single center randomized double blind controlled study of patients (BMI ≥ 27 kg/m2) with obesity and Atrial Fibrillation (AFIB) randomized to Tirzepatide vs. placebo. It is expected that the significant weight loss with Tirzepatide will result in improved control, management, symptom severity, and burden of AFIB at 12 months.

Treatments tested

Tirzepatide also known as Zepbound Drug

Weekly subcutaneous injections starting with dose 2.5mg, then increase dose by 2.5mg at week 4 (5mg), week 8 (7.5mg) and at week12 (10mg) as tolerated.
Placebo also known as Normal Saline Drug

Weekly subcutaneous injections starting with dose 2.5mg, then increase dose by 2.5mg at week 4 (5mg), week 8 (7.5mg) and at week 12 (10mg).

Main thing measured	AFib burden
Sponsor	The Cleveland Clinic
Conditions studied	Atrial Fibrillation, Obesity
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06802081 ↗